Evaxion Biotech A/S (NASDAQ:EVAX) Sees Large Decline in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 22,400 shares, a decline of 74.2% from the February 28th total of 86,700 shares. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is currently 0.0 days. Approximately 2.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on EVAX shares. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th. Lake Street Capital decreased their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th.

Evaxion Biotech A/S Price Performance

EVAX stock remained flat at $1.76 during mid-day trading on Friday. The company’s stock had a trading volume of 39,037 shares, compared to its average volume of 594,950. The firm’s 50 day simple moving average is $2.49 and its two-hundred day simple moving average is $7.29. The company has a market cap of $2.06 million, a PE ratio of -1.21 and a beta of -0.25. Evaxion Biotech A/S has a 52-week low of $1.67 and a 52-week high of $22.05. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.